Strategic Partnerships Leverage Fosun Pharma USA’s track record of international collaborations and recent partnerships (AriBio, Fakeeh Care Group, Henlius licensing) to propose co-development or distribution agreements for high-value injectables and ophthalmics in the US market.

US Market Entry Target opportunities around commercialization and market access for innovative therapies sourced from Fosun Pharma Group, including exclusive licensing, distribution, and co-promotional deals in specialty segments with limited competition.

Portfolio Fit Position the US portfolio of specialty injectables and ophthalmics for strategic alignment with mid-to-high growth therapeutic areas, emphasizing faster regulatory pathways, orphan/rare disease potential, and high-margin branded products.

Innovation Channel Capitalize on Fosun’s R&D model and recent vaccine/anticancer collaborations to explore United States pilot programs, alliance-driven manufacturing, and accelerated access programs for early-stage, high-demand assets.

Global Financing Highlight potential for joint ventures or financing-backed initiatives (including international facility expansions and strategic partnerships) to support scale-up, international supply resilience, and diversification of US revenue channels.